WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present a…
Author: Business Wire
Aerie Pharmaceuticals to Participate in the Bank of America Securities 2021 Healthcare Conference
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glauco…
Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseas…
Global Dry Eye Epidemiology and Patient Flow Report 2021: Prevalence and Incidence and Patient by Age-Gender 2020-2035 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Dry Eye Epidemiology and Patient Flow – 2021” report has been added to ResearchAndMarkets.com’s offering. The research report, Global Dry Eye Epidemiology and Patient Flow Analysis – 2021, provides Dry Eye epidemiol…
Global Wet Age-Related Macular Degeneration Epidemiology and Patient Flow to 2035: Focus on United States, Germany, France, Italy, Spain, UK, Japan, & G7 Countries – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Wet Age-Related Macular Degeneration Epidemiology and Patient Flow – 2021” report has been added to ResearchAndMarkets.com’s offering. Global Wet Age-Related Macular Degeneration Epidemiology and Patient Flow Analys…
Glaukos Corporation Announces First Quarter 2021 Financial Results
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced finan…
STAAR Surgical Reports Record First Quarter 2021 Net Sales of $50.8 Million Up 44% Y/Y
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the first quarter ended A…
Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business Update
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today r…
Aerie Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Zenni Partners with Eyewear Icon Iris Apfel to Launch “The Iris Apfel Edit”– the First in a Series of Collections with the Soon-to-Be Centenarian
NOVATO, Calif.–(BUSINESS WIRE)–Zenni, the online eyewear retail leader, today announced an exclusive Iris X Zenni partnership with larger-than-life style icon, eyewear aficionado and self-proclaimed “geriatric starlet” Iris Apfel. The multi-year part…
OcuTerra Strengthens Board of Directors with Three New Key Appointments
BOSTON–(BUSINESS WIRE)–OcuTerra Therapeutics appoints Brent Saunders, Robert Ruffolo, Ph.D., and Robin Steele to its Board of Directors
Lineage Announces Appointment of Anula Jayasuriya, M.D., PH.D., M.B.A., to Board of Directors
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCell–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced the appoi…
LENSAR Reports First Quarter 2021 Financial Results and Provides Business Update
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for …
Iveric Bio Reports First Quarter 2021 Operational Highlights and Financial Results
NEW YORK–(BUSINESS WIRE)–Iveric Bio announced financial and operating results for the quarter ended March 31, 2021 and provided a general business update.
Global Dry Age-Related Macular Degeneration Epidemiology and Patient Flow Report 2020-2035: Identify Patient Segments Through Age Groups, Gender, and Disease Sub-types – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Dry Age-Related Macular Degeneration Epidemiology and Patient Flow – 2021” report has been added to ResearchAndMarkets.com’s offering. Global Dry Age-Related Macular Degeneration Epidemiology and Patient Flow Analys…
Alcon Reports First Quarter 2021 Results
GENEVA–(BUSINESS WIRE)–Alcon Reports First Quarter 2021 Results
Alcon Reports First Quarter 2021 Results
GENEVA–(BUSINESS WIRE)–Alcon Reports First Quarter 2021 Results
Santen annonce l’approbation de PRESERFLOMC MicroShunt par Santé Canada
TORONTO–(BUSINESS WIRE)–Santen Canada Inc., filiale de Santen Pharmaceutical Co., Ltd. (« Santen »), société internationale vouée exclusivement à l’ophtalmologie, a annoncé aujourd’hui l’approbation de PRESERFLOMC MicroShunt par Santé Canada. PRESERF…
Santen Announces Health Canada Approval of PRESERFLO MicroShunt
TORONTO–(BUSINESS WIRE)–Santen Announces Health Canada Approval of PRESERFLO MicroShunt
Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced new preclini…